Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olaf Penack

Showing results (21-30 of 184) with videos related to

Pageof 19
Sort By:
Experimental Hematology|May 27, 2006
The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cellsLars Fischer, Olaf Penack, Chiara Gentilini, et al.
The Ocular Surface|May 8, 2026
Prospective evaluation of patient reported outcome measures (PROMs) and correlation with clinical parameters of chronic ocular graft-versus-host disease (GVHD)Jonas Milek, Olaf Penack, Igor-Wolfgang Blau, et al.
International Journal of Molecular Sciences|July 2, 2021
Ocular Graft-versus-Host Disease in a Chemotherapy-Based Minor-Mismatch Mouse Model Features Corneal (Lymph-) AngiogenesisUta Gehlsen, Daniela Stary, Martina Maass, et al.
Hematology (Amsterdam, Netherlands)|June 10, 2022
Effectiveness and safety of isavuconazole prophylaxis for invasive fungal infections in the haematologic settingYang Ping, Jing Hongmei, Christian Bellmann, et al.
Future Microbiology|August 29, 2023
A plain language summary on preventing fungal infections with isavuconazole in people with blood-related conditionsYang Ping, Jing Hongmei, Christian Bellmann, et al.
Blood|January 19, 2017
Lymphangiogenesis is a feature of acute GVHD, and VEGFR-3 inhibition protects against experimental GVHDSarah Mertlitz, Yu Shi, Martina Kalupa, et al.
Bone Marrow Transplantation|November 29, 2022
Steroid-free first line treatment of moderate and severe chronic GVHD: a survey from the Transplant Complications Working Party of the EBMTIvan Moiseev, Pascale Ambron, Manuela Badoglio, et al.
Transplant Immunology|November 17, 2007
The type of ATG matters -- natural killer cells are influenced differentially by Thymoglobulin, Lymphoglobulin and ATG-FreseniusOlaf Penack, Lars Fischer, Chiara Gentilini, et al.
Haematologica|May 30, 2024
Management of complications of chimeric antigen receptor T-cell therapy: a report by the European Society of Blood and Marrow TransplantationOlaf Penack, Christophe Peczynski, William Boreland, et al.
JMIR Cancer|November 10, 2023
Understanding the Needs and Lived Experiences of Patients With Graft-Versus-Host Disease: Real-World European Public Social Media Listening StudyZinaida Perić, Grzegorz Basak, Christian Koenecke, et al.
Pageof 19

Showing results (21-30 of 184) with videos related to

Sort By:
Pageof 19
Experimental Hematology|May 27, 2006
The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cellsLars Fischer, Olaf Penack, Chiara Gentilini, et al.
The Ocular Surface|May 8, 2026
Prospective evaluation of patient reported outcome measures (PROMs) and correlation with clinical parameters of chronic ocular graft-versus-host disease (GVHD)Jonas Milek, Olaf Penack, Igor-Wolfgang Blau, et al.
International Journal of Molecular Sciences|July 2, 2021
Ocular Graft-versus-Host Disease in a Chemotherapy-Based Minor-Mismatch Mouse Model Features Corneal (Lymph-) AngiogenesisUta Gehlsen, Daniela Stary, Martina Maass, et al.
Hematology (Amsterdam, Netherlands)|June 10, 2022
Effectiveness and safety of isavuconazole prophylaxis for invasive fungal infections in the haematologic settingYang Ping, Jing Hongmei, Christian Bellmann, et al.
Future Microbiology|August 29, 2023
A plain language summary on preventing fungal infections with isavuconazole in people with blood-related conditionsYang Ping, Jing Hongmei, Christian Bellmann, et al.
Blood|January 19, 2017
Lymphangiogenesis is a feature of acute GVHD, and VEGFR-3 inhibition protects against experimental GVHDSarah Mertlitz, Yu Shi, Martina Kalupa, et al.
Bone Marrow Transplantation|November 29, 2022
Steroid-free first line treatment of moderate and severe chronic GVHD: a survey from the Transplant Complications Working Party of the EBMTIvan Moiseev, Pascale Ambron, Manuela Badoglio, et al.
Transplant Immunology|November 17, 2007
The type of ATG matters -- natural killer cells are influenced differentially by Thymoglobulin, Lymphoglobulin and ATG-FreseniusOlaf Penack, Lars Fischer, Chiara Gentilini, et al.
Haematologica|May 30, 2024
Management of complications of chimeric antigen receptor T-cell therapy: a report by the European Society of Blood and Marrow TransplantationOlaf Penack, Christophe Peczynski, William Boreland, et al.
JMIR Cancer|November 10, 2023
Understanding the Needs and Lived Experiences of Patients With Graft-Versus-Host Disease: Real-World European Public Social Media Listening StudyZinaida Perić, Grzegorz Basak, Christian Koenecke, et al.
Pageof 19